Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter 
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

Johnson & Johnson Seeks Full FDA Approval for HIV Treatment

February 13, 2009

Johnson & Johnson's Tibotec unit is requesting full Food and Drug Administration approval of its HIV drug Intelence, a non-nucleoside reverse transcriptase inhibitor designed for patients who have stopped responding to other treatments. FDA in January gave the drug preliminary approval under its accelerated approval program, allowing the company to market Intelence. In order to gain full approval, FDA required Tibotec to supply follow-up data on the drug's effectiveness. According to data submitted by Tibotec, 60 percent of patients taking Intelence for four months had undetectable HIV levels in their blood, compared with 39 percent of patients taking a placebo.

Back to other news for February 2009

Adapted from:
Associated Press
02.05.2009


  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
More HIV News


Advertisement